New Hope for Osteoarthritis: LEVI-04 Aims to Halt Pain and Disease

SANDWICH, UK – March 30, 2026 – Millions of people living with the chronic pain of osteoarthritis may have a new reason for hope, following the publication of groundbreaking clinical trial results in the prestigious medical journal The Lancet. The study details the success of a first-in-class drug, LEVI-04, which has demonstrated a remarkable ability to not only significantly reduce pain but also potentially halt the progression of the disease itself.

Developed by UK-based biotechnology firm Levicept Ltd, LEVI-04 has emerged from a rigorous Phase II clinical trial as a potential game-changer in a therapeutic area that has seen little innovation for decades. The international, double-blind, placebo-controlled study, which enrolled 518 patients with moderate-to-severe knee osteoarthritis, showed that the treatment was highly effective and well-tolerated, marking a pivotal moment for both the company and patients worldwide.

A Breakthrough in Pain and Function

The results published in The Lancet outline a clear and statistically significant victory over pain. Patients receiving LEVI-04 experienced substantial improvements across all tested doses compared to those on a placebo. The primary goal of the study was to measure a reduction in pain using the widely recognized WOMAC pain score, and the results were compelling. More than half of the patients treated with LEVI-04 reported at least a 50% reduction in their pain levels, while more than a quarter experienced a dramatic 75% reduction.

These are not just numbers on a chart; they represent a meaningful return to daily life for individuals often debilitated by the condition. Beyond pain, patients also reported significant improvements in joint stiffness and physical function, as measured by secondary endpoints and Patient Global Assessment scores. The treatment’s safety profile was equally impressive, with adverse event rates similar to the placebo group and no evidence of the joint-related side effects that have hindered the development of other novel pain therapies.

Professor Philip Conaghan, the study's Chief Investigator and lead author of The Lancet publication, underscored the gravity of the findings. “The potential benefits of this treatment for patients are very significant,” he stated. “Osteoarthritis impacts on all aspects of people’s lives and there are limited therapy options currently to manage the symptoms. This has left us and our patients with very few choices to relieve the discomfort caused by the condition.”

Professor Conaghan described LEVI-04 as a potential “game-changer,” adding that it “offers the possibility to be a game-changer, giving us better options to treat the pain faced by patients, and with further possibilities to unlock new treatments in the future.”

Beyond Symptom Relief: The Promise of Disease Modification

What sets LEVI-04 apart and generates immense excitement in the medical community is its potential to be a true Disease-Modifying Osteoarthritis Drug (DMOAD)—the holy grail of OA research. For years, treatments have focused on managing symptoms like pain and inflammation with NSAIDs, steroid injections, and, in severe cases, opioids, none of which stop the underlying joint degeneration.

Levicept presented further data analysis at the American College of Rheumatology (ACR) Convergence 2025 meeting that provided the first clinical evidence of this disease-modifying potential. The analysis showed that LEVI-04 had a positive, dose-dependent effect on bone marrow lesions—areas of damage in the subchondral bone that are strongly associated with pain and disease progression in osteoarthritis. This suggests the drug may be directly intervening in the disease process, protecting the joint structure from further degradation.

Simon Westbrook, Levicept's Founder, Chief Scientific Officer, and senior author of the publication, highlighted this unique dual action. “We believe LEVI-04 has a unique profile as a new treatment option for OA,” he said. “As shown in The Lancet publication, LEVI-04 significantly reduces pain and symptoms of OA. Separately, we have also demonstrated potential to directly address the OA disease process. We believe it is the only molecule to have demonstrated both analgesia and the potential for disease modification in a clinical study in patients with OA.”

This dual mechanism works by targeting neurotrophins, proteins involved in nerve signaling. By selectively inhibiting neurotrophin-3 (NT-3) with a p75 neurotrophin receptor fusion protein, LEVI-04 is designed to provide powerful pain relief while avoiding the safety issues that plagued earlier attempts to modulate this pathway.

Navigating a Competitive Landscape

The success of LEVI-04 comes at a critical time. The global market for osteoarthritis treatments, valued at nearly $10 billion, is ripe for disruption. The aging global population and rising obesity rates are driving an epidemic of OA, placing an enormous burden on healthcare systems and diminishing the quality of life for hundreds of millions.

While the pipeline for new OA drugs is more active than it has been in years, few candidates offer the dual-action profile seen with LEVI-04. Other late-stage contenders, such as Biosplice Therapeutics' Lorecivivint, are also being investigated as potential DMOADs, but they operate through different biological pathways. The distinct mechanism of LEVI-04, coupled with its strong safety and efficacy data, positions it as a formidable and highly differentiated candidate in the race to transform OA care.

Levicept's journey itself is a story of scientific persistence. The core asset, LEVI-04, was discovered by Simon Westbrook at Pfizer's UK research campus. When Pfizer closed the site in 2011, Westbrook founded Levicept to acquire the asset and continue its development. The company has since attracted significant investment from top-tier venture firms, including Advent Life Sciences, Gilde Healthcare, Medicxi, and notably, Pfizer's own venture arm, Pfizer Ventures.

With the successful completion of the Phase II trial and the acceptance of an Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) in January 2026, Levicept is now poised to advance LEVI-04 into pivotal Phase III trials. The recent appointment of seasoned biotech executive Eliot Forster as CEO signals the company's focus on navigating this final, crucial stage of clinical development and preparing for a potential path to market. The next phase of trials will be essential to confirm these promising results in a larger patient population and solidify LEVI-04's place as a revolutionary new standard of care for osteoarthritis.